All In Biotech

Drug Trial Radar · NCT02753946

Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

Last checked: Nov 19, 2026Latest source record: Mar 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

465

Actual

Start

Apr 2016

Primary completion

Jan 12, 2017

Study completion May 30, 2017

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Apr 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin) as non-inferior to piperacillin/tazobactam in overall success (clinical cure and microbiologic eradication) for the treatment of hospitalized patients with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP).

Conditions

  • Urinary Tract Infection Symptomatic
  • Acute Pyelonephritis
  • Urinary Tract Infection Complicated

Interventions

  • ZTI-01Drug

    6g ZTI-01 intravenous infusion TID q8 hours

  • Piperacillin-tazobactamDrug

    4.5g piperacillin-tazobactam intravenous infusion TID q8 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With an Overall SuccessTime frame: TOC Visit (Day 19)

Locations

68 sites in 16 countries. Site status is shown where the registry gives one.

  • Site not named

    Pensacola, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Boylston, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Butte, Montana

  • Site not named

    Brest, Belarus

  • Site not named

    Grodno, Belarus

  • Site not named

    Homyel, Belarus

  • Site not named

    Minsk, Belarus

  • Site not named

    Vitebsk, Belarus

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Slavonski Brod, Croatia

  • Site not named

    Split, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Liberec, Czechia

  • Site not named

    Kohtla-Järve, Estonia

  • Site not named

    Tallinn, Estonia

  • Site not named

    Batumi, Georgia

  • Site not named

    Kutaisi, Georgia

  • Site not named

    Tbilisi, Georgia

  • Site not named

    Ampelokipoi, Greece

  • Site not named

    Athens, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    Budapest, Hungary

  • Site not named

    Miskolc, Hungary

  • Site not named

    Nagykanizsa, Hungary

  • Site not named

    Pécs, Hungary

  • Site not named

    Szekszárd, Hungary

  • Site not named

    Szentes, Hungary

  • Site not named

    Riga, Latvia

  • Site not named

    Valmiera, Latvia

  • Site not named

    Kaunas, Lithuania

  • Site not named

    Klaipėda, Lithuania

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Bielsko-Biala, Poland

  • Site not named

    Krakow, Poland

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.